Clearly, if this was just a vaccine company I wouldn't be considering divesting the vaccine arm... but then I wouldn't have a choice, would I? In this case I think the company would be better off in the short to medium term as the long term payoff is a punt.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-52
-
- There are more pages in this discussion • 299 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
-0.380(2.42%) |
Mkt cap ! $323.4M | |||
| Open | High | Low | Value | Volume |
| $15.70 | $15.94 | $15.02 | $290.0K | 18.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280 | $15.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.57 | 779 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |